ARCHIVES

Recurrent Multiple Myeloma Responds To Revimid In Phase II, Side Effects Tolerable

This article is from The Cancer Letter archive.

Vol. 26 No. 1 | January 31, 2003

Download PDF Visit The Full Archive

Related Articles

NIH Funding Opportunities Listed

March 13, 2009

CCRU RFA Reissued, Outstanding Investigator Grants Now Available, CCSPs Changed To Program Projects

April 20, 1984

Mammography Quality Standards Set, FDA User Fees Enacted; Oral Cancer Drugs Covered

October 16, 1992

Basic Research Group Seeks $7.9 Billion For NIH, $1.7 For NCI

July 24, 1987

Obituaries: Fritz Bach, 77, and William Wolff, 94

September 9, 2011

UNC Lineberger Appoints Two, Zaret Wins Chair At Fox Chase.

February 25, 2000